Skip to content
TickerMagic

Ind-Swift Laboratories Limited

INDSWFTLABNSEHealthcare
₹330.2
-6.55 (-1.95%) · EOD 2026-11-20

Our verdict

Sell

Quality (42/100) does the heavy lifting; financial trend (0/100) is the drag.

Buy zoneHealth BOvervalued
Quality 42Momentum 42Value 39Trend 0The Spark ↓

Our fair value

Overvalued by 45%
₹180.62down 45.30%
Price ₹330Range ₹165 – ₹195

Buy-below (20% margin of safety): ₹144.5

The bottom line

Ind-Swift Laboratories Limited earns a Sell from TickerMagic, with a blended score of 33/100. We put fair value near ₹180.62; at ₹330.2 that leaves roughly 45% downside, so the stock screens overvalued by 45%. On 40.1x trailing earnings it sits roughly in line with the Healthcare median of about 37.4x. The price is about 20% below its 52-week high of ₹413.1 and 275% above the low of ₹88.15. Financial health scores 79/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 4 of 13 investability checks, with durability 42, valuation 78 and momentum 42 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹180.62down 45.30%
Overvalued by 45%
Price ₹330.2Range ₹165.1–₹195.07
Relative multipleslow confidence

With a 20% margin of safety, our buy-below price is ₹144.5. Low-confidence estimate — limited data.

1-year price

EOD · 2026-11-20
1D
down 1.95%
1W
down 8.37%
1M
down 6.17%
3M
down 4.81%
6M
up 145.08%
1Y
—

52-week range

-20.07% from the 52-week high.

Trend check
Below 50-DMA₹370Above 200-DMA₹231

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell33
B
Financial health 79/100
Altman Z 4.17 · Safe zone

Piotroski F-score 2/9 — quality of earnings & balance sheet.

Our scores

Durability42
Valuation78
Momentum42

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 4 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 3.2%
  • Pass: Low debt (D/E < 0.5): 0.01x
  • Fail: Positive free cash flow
  • Fail: Revenue growth > 10%: -67%
  • Fail: Earnings growing: -95%
  • Fail: Net margin ≥ 10%: 6.5%
  • Pass: Current ratio > 1.5: 3.80
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 4.17
  • Fail: Piotroski ≥ 7: 2/9

Shareholding

  • Promoter59.4%
  • Institutions4.6%
  • Public & other35.9%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹1,686 Cr
P/E ratio
40.1
P/B ratio
1.17
EPS (TTM)
₹4.83
ROE
3.2%
Debt / Equity
0.01x
Profit margin
6.5%
Free cash flow
₹-141 Cr
52-week high
₹413.1
-20.07% from high
52-week low
₹88.15
Dividend yield
—
Beta
0.62
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 4.17.

Opportunities

  • Trading in our value buy zone versus sector peers.

Bear case

Weaknesses

  • Low return on equity (3.2%).
  • Weak Piotroski score (2/9).

Threats

  • Earnings contracting year on year.
  • Trades ~45% above our estimated fair value.

About Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients, intermediates, and formulations across multiple therapeutic areas including macrolide antibiotics, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyroidism, analgesic, aromatase inhibitor, and nootropic treatments. The company operates in India and internationally.

Ind-Swift Laboratories Limited — frequently asked questions

Is Ind-Swift Laboratories Limited a buy, hold or sell?

TickerMagic currently rates Ind-Swift Laboratories Limited (INDSWFTLAB) a Sell, based on a blended score of 33/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Ind-Swift Laboratories Limited's fair value?

Our blended DCF and relative-valuation model estimates Ind-Swift Laboratories Limited's fair value at about ₹180.62, versus a current price of ₹330.2 — roughly 45% downside. On that basis the stock looks overvalued by 45%.

Is Ind-Swift Laboratories Limited financially healthy?

Ind-Swift Laboratories Limited scores 79/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.

How has Ind-Swift Laboratories Limited's share price performed?

Ind-Swift Laboratories Limited is down 5% over three months, and last traded at ₹330.2. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.